These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24984937)

  • 1. Benzoquinones as inhibitors of botulinum neurotoxin serotype A.
    Bremer PT; Hixon MS; Janda KD
    Bioorg Med Chem; 2014 Aug; 22(15):3971-81. PubMed ID: 24984937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A.
    Bremer PT; Pellett S; Carolan JP; Tepp WH; Eubanks LM; Allen KN; Johnson EA; Janda KD
    J Am Chem Soc; 2017 May; 139(21):7264-7272. PubMed ID: 28475321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies.
    Šilhár P; Silvaggi NR; Pellett S; Čapková K; Johnson EA; Allen KN; Janda KD
    Bioorg Med Chem; 2013 Mar; 21(5):1344-8. PubMed ID: 23340139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of library of betulin derivatives against the botulinum neurotoxin A protease.
    Šilhár P; Alakurtti S; Čapková K; Xiaochuan F; Shoemaker CB; Yli-Kauhaluoma J; Janda KD
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2229-31. PubMed ID: 21421315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors.
    Thompson JC; Dao WT; Ku A; Rodriguez-Beltran SL; Amezcua M; Palomino AY; Lien T; Salzameda NT
    Bioorg Med Chem; 2020 Sep; 28(18):115659. PubMed ID: 32828426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compounds.
    Minnow YV; Goldberg R; Tummalapalli SR; Rotella DP; Goodey NM
    Arch Biochem Biophys; 2017 Mar; 618():15-22. PubMed ID: 28137423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.
    Li B; Pai R; Cardinale SC; Butler MM; Peet NP; Moir DT; Bavari S; Bowlin TL
    J Med Chem; 2010 Mar; 53(5):2264-76. PubMed ID: 20155918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual medicinal chemistry: in silico pre-docking functional group transformation for discovery of novel inhibitors of botulinum toxin serotype A light chain.
    O'Malley S; Sareth S; Jiao GS; Kim S; Thai A; Cregar-Hernandez L; McKasson L; Margosiak SA; Johnson AT
    Bioorg Med Chem Lett; 2013 May; 23(9):2505-11. PubMed ID: 23545109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of α-exosite inhibitors against Botulinum neurotoxin A protease through structure-activity relationship studies of chicoric acid.
    Xue S; Seki H; Remes M; Šilhár P; Janda K
    Bioorg Med Chem Lett; 2017 Nov; 27(22):4956-4959. PubMed ID: 29050781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum neurotoxin inhibitor binding dynamics and kinetics relevant for drug design.
    Patel KB; Kononova O; Cai S; Barsegov V; Parmar VS; Kumar R; Singh BR
    Biochim Biophys Acta Gen Subj; 2021 Sep; 1865(9):129933. PubMed ID: 34023445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the β-exosite.
    Smith GR; Caglič D; Capek P; Zhang Y; Godbole S; Reitz AB; Dickerson TJ
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3754-7. PubMed ID: 22542019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing BoNT/A protease exosites: implications for inhibitor design and light chain longevity.
    Xue S; Javor S; Hixon MS; Janda KD
    Biochemistry; 2014 Nov; 53(43):6820-4. PubMed ID: 25295706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease.
    Opsenica I; Filipovic V; Nuss JE; Gomba LM; Opsenica D; Burnett JC; Gussio R; Solaja BA; Bavari S
    Eur J Med Chem; 2012 Jul; 53():374-9. PubMed ID: 22516424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVALENT INHIBITION OF BOTULINUM NEUROTOXIN A - EXPLORATION OF WARHEAD REACTIVITY AND FUNCTION USING A BIFUNCTIONAL APPROACH.
    Turner LD; Nielsen AL; Lin L; Pellett S; Sugane T; Olson ME; Janda KD
    Toxicon; 2021 Jan; 190(Suupl 1):S72-S73. PubMed ID: 34103769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.
    Li B; Cardinale SC; Butler MM; Pai R; Nuss JE; Peet NP; Bavari S; Bowlin TL
    Bioorg Med Chem; 2011 Dec; 19(24):7338-48. PubMed ID: 22082667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease.
    Stowe GN; Silhár P; Hixon MS; Silvaggi NR; Allen KN; Moe ST; Jacobson AR; Barbieri JT; Janda KD
    Org Lett; 2010 Feb; 12(4):756-9. PubMed ID: 20092262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to Counteract Botulinum Neurotoxin A: Nature's Deadliest Biomolecule.
    Lin L; Olson ME; Eubanks LM; Janda KD
    Acc Chem Res; 2019 Aug; 52(8):2322-2331. PubMed ID: 31322847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A.
    Teng YH; Berger WT; Nesbitt NM; Kumar K; Balius TE; Rizzo RC; Tonge PJ; Ojima I; Swaminathan S
    Bioorg Med Chem; 2015 Sep; 23(17):5489-95. PubMed ID: 26275678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A.
    Roxas-Duncan V; Enyedy I; Montgomery VA; Eccard VS; Carrington MA; Lai H; Gul N; Yang DC; Smith LA
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3478-86. PubMed ID: 19528275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility.
    Thompson AA; Jiao GS; Kim S; Thai A; Cregar-Hernandez L; Margosiak SA; Johnson AT; Han GW; O'Malley S; Stevens RC
    Biochemistry; 2011 May; 50(19):4019-28. PubMed ID: 21434688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.